This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Soligenix advances HyBryte, a visible light photodynamic therapy for rare cutaneous T-cell lymphoma, with Phase 3 interim results expected early 2026. Novel approach offers faster response and favorable safety profile. #RareDisease #Biotech
2026-05-15T06:28:35.574Z